Guided Therapeutics (GTHP) Interest Income - Total (2023 - 2024)

Guided Therapeutics' (GTHP) quarterly Interest Income - Total came in at $3000.0 in Q1 2024, down 50.0% quarter-over-quarter from $6000.0 in Q4 2023.

Guided Therapeutics (GTHP) Interest Income - Total (2023 - 2024) Analysis & Trends

Guided Therapeutics has disclosed Interest Income - Total across 2 years of filings, most recently posting $3000.0 for Q1 2024.

Interest Income - Total for Q1 2024 came in at $3000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $3000.0 (down 50.0% YoY), and the FY2024 annual result was $3000.0, down 50.0% from the prior year.
Interest Income - Total came in at $3000.0 for Q1 2024 at Guided Therapeutics, down from $6000.0 in the prior quarter.
In the past five years, Interest Income - Total ranged from a high of $6000.0 in Q4 2023 to a low of $3000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Income - Total (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	-
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Guided Therapeutics	-	-	458,000.00	-

Download Data